LYPD3

Summary

LYPD3 (LY6/PLAUR domain containing 3, HGNC:24880) is a protein-coding gene on chromosome 19q13.31, encoding Ly6/PLAUR domain-containing protein 3 (O95274). Supports cell migration.

Predicted to enable laminin binding activity. Involved in negative regulation of smooth muscle cell apoptotic process. Located in extracellular space.

Source: NCBI Gene 27076 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 61 total
• MANE Select transcript: NM_014400

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24880
Approved symbol	LYPD3
Name	LY6/PLAUR domain containing 3
Location	19q13.31
Locus type	gene with protein product
Status	Approved
Aliases	C4.4A
Ensembl gene	ENSG00000124466
Ensembl biotype	protein_coding
OMIM	609484
Entrez	27076

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 3 retained_intron, 1 protein_coding

ENST00000244333, ENST00000594326, ENST00000595970, ENST00000597741

RefSeq mRNA: 1 — MANE Select: NM_014400 NM_014400

CCDS: CCDS12620

Canonical transcript exons

ENST00000244333 — 5 exons

Exon	Start	End
ENSE00000847411	43460787	43461847
ENSE00000847415	43465493	43465608
ENSE00001161659	43463599	43463769
ENSE00003472194	43463126	43463287
ENSE00003672141	43464325	43464456

Expression profiles

Bgee: expression breadth ubiquitous, 199 present calls, max score 99.70.

FANTOM5 (CAGE): breadth broad, TPM avg 5.4228 / max 285.8621, expressed in 346 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
181270	4.1405	266
181272	0.6425	219
181271	0.4860	205
181273	0.0845	41
181268	0.0409	20
181269	0.0284	7

Top tissues by expression

291 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
gingival epithelium	UBERON:0001949	99.70	gold quality
lower esophagus mucosa	UBERON:0035834	99.63	gold quality
gingiva	UBERON:0001828	99.61	gold quality
cervix squamous epithelium	UBERON:0006922	99.45	gold quality
pharyngeal mucosa	UBERON:0000355	99.44	gold quality
skin of abdomen	UBERON:0001416	99.34	gold quality
tongue squamous epithelium	UBERON:0006919	99.14	gold quality
nipple	UBERON:0002030	99.12	gold quality
upper arm skin	UBERON:0004263	99.09	gold quality
squamous epithelium	UBERON:0006914	99.07	gold quality
esophagus mucosa	UBERON:0002469	99.01	gold quality
mammalian vulva	UBERON:0000997	98.98	gold quality
cervix epithelium	UBERON:0004801	98.98	gold quality
penis	UBERON:0000989	98.93	gold quality
skin of leg	UBERON:0001511	98.85	gold quality
zone of skin	UBERON:0000014	98.82	gold quality
upper leg skin	UBERON:0004262	98.79	gold quality
esophagus squamous epithelium	UBERON:0006920	98.67	gold quality
body of tongue	UBERON:0011876	98.42	gold quality
oral cavity	UBERON:0000167	98.39	gold quality
epithelium of esophagus	UBERON:0001976	98.09	gold quality
skin of hip	UBERON:0001554	96.51	gold quality
tongue	UBERON:0001723	95.67	gold quality
vagina	UBERON:0000996	93.69	gold quality
hair follicle	UBERON:0002073	93.22	gold quality
palpebral conjunctiva	UBERON:0001812	92.14	gold quality
amniotic fluid	UBERON:0000173	91.52	gold quality
superior surface of tongue	UBERON:0007371	91.40	gold quality
tonsil	UBERON:0002372	88.77	gold quality
mouth mucosa	UBERON:0003729	88.21	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-MTAB-8142	yes	3660.98
E-HCAD-1	yes	1511.57
E-CURD-114	yes	428.55
E-MTAB-6701	yes	47.72
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CEBPB, FOXC1, JUN, JUND, SP1, SP3

miRNA regulators (miRDB)

42 targeting LYPD3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-3681-3P	99.88	70.46	2254
HSA-MIR-3617-5P	99.75	69.41	1968
HSA-MIR-641	99.75	69.35	1975
HSA-MIR-1255A	99.74	68.09	744
HSA-MIR-1255B-5P	99.74	68.16	741
HSA-MIR-6752-3P	99.72	66.71	1587
HSA-MIR-7-5P	99.67	70.53	1809
HSA-MIR-1827	99.63	68.57	3265
HSA-MIR-6716-5P	99.56	68.62	1244
HSA-MIR-186-3P	99.51	66.24	1685
HSA-MIR-5584-5P	99.49	68.22	2814
HSA-MIR-1253	99.12	67.08	1688
HSA-MIR-4738-3P	98.98	67.98	1846
HSA-MIR-6770-5P	98.97	66.76	1853
HSA-MIR-455-3P	98.94	67.68	878
HSA-MIR-1304-5P	98.90	68.58	1054
HSA-MIR-2355-5P	98.83	65.51	1589
HSA-MIR-455-5P	98.74	67.31	795

Literature-anchored findings (GeneRIF, showing 20)

• hAG-2 and hAG-3, human homologues of genes involved in differentiation, are associated with oestrogen receptor-positive breast tumours and interact with metastasis gene C4.4a and dystroglycan (PMID:12592373)
• High tumour cell C4.4A expression is associated with shorter survival for non-small cell lung cancer patients. (PMID:17706320)
• Overexpression of C4.4A is associated with invasion and metastasis of esophageal squamous cell carcinoma (PMID:17849475)
• we consider C4.4A as a candidate diagnostic marker in colorectal cancer, which possibly can be detected in body fluids (PMID:17912244)
• cleavage of C4.4A by ADAM10 and ADAM17 contributes to tumor progression (PMID:18979631)
• data indicate that expression of the C4.4A protein at the invasive front acts as a novel prognostic marker in colorectal cancer, possibly through invasion-related mechanisms (PMID:20825414)
• findings suggest that a tight association between C4.4A and tumor budding may, in part, be due to C4.4A promoting epithelial-mesenchymal transition at the invasive front of colorectal cancer (PMID:22404718)
• the first explanation for the C4.4A contribution to wound healing and metastasis. (PMID:22431918)
• Tenascin-C expression was significantly associated with C4.4A expression in clinical esophageal squamous carcinoma samples suggesting that there may be a functional role for the C4.4A to induceTenascin-C in vivo. (PMID:23708783)
• Highly expressed C4.4A protein in HER2-positive human breast cancers indicate a good prognosis. (PMID:23918676)
• overexpression of C4.4A correlates with metastatic potential of gastric cancer and C4.4A could be a novel independent prognostic marker for predicting outcome. (PMID:24935570)
• expression of the Ly6/uPAR-domain proteins C4.4A and Haldisin in non-invasive and invasive skin lesions (PMID:25414274)
• LYPD3 has a role in the maintenance of colorectal cancer stem-like cells. (PMID:28238780)
• Expression and crystallographic studies of the D1D2 domains of C4.4A have been reported. (PMID:28777093)
• While in the healthy liver hepatocytes are C4.4A negative, data show that C4.4A is strongly expressed in hepatocellular carcinoma (HCC) with upregulation at the invasive front and in lung metastasis, indicating that C4.4A apparently contributes to HCC progression. (PMID:29048672)
• Our results are consistent with previous data in mouse embryogenesis and wound healing. Based on these findings, we conclude that this human TES model provides an excellent surrogate for studies of C4.4A and Haldisin expressions in human stratified epithelia. (PMID:29075641)
• Long non-coding RNA OGFRP1 contributed to progression of non-small cell lung cancer at least partly through upregulating LYPD3 expression by sponging miR-124-3p. (PMID:30274775)
• The authors explored the related pathways through which LYPD3 affects the pathogenesis and prognosis of lung adenocarcinoma by gene set enrichment analysis, and found that LYPD3 might affect the clinical manifestations of lung adenocarcinoma by regulating the P53 signaling pathway. (PMID:32040344)
• LY6/PLAUR domain containing 3 (LYPD3) maintains melanoma cell stemness and mediates an immunosuppressive microenvironment. (PMID:37924160)
• m6A-dependent mature miR-151-5p accelerates the malignant process of HNSCC by targeting LYPD3. (PMID:39009906)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Lypd3	ENSMUSG00000057454
rattus_norvegicus	Lypd3	ENSRNOG00000019999

Paralogs (2): PLAUR (ENSG00000011422), LYPD5 (ENSG00000159871)

Protein

Protein identifiers

Ly6/PLAUR domain-containing protein 3 — O95274 (reviewed: O95274)

Alternative names: GPI-anchored metastasis-associated protein C4.4A homolog, Matrigel-induced gene C4 protein

All UniProt accessions (2): B2RBR3, O95274

UniProt curated annotations — full annotation on UniProt →

Function. Supports cell migration. May be involved in urothelial cell-matrix interactions. May be involved in tumor progression.

Subunit / interactions. Binds laminin-1 and laminin-5. Interacts with LGALS3. Interacts with AGR2 and AGR3.

Subcellular location. Cell membrane.

Tissue specificity. Expressed in placenta, skin and urothelium. Found in suprabasal keratinocytes of chronic wounds. Weak expression is found in esophagus and peripheral blood mononuclear cells. Found in the majority of primary and metastatic transitional cell carcinomas (TCCs) and as well in breast cancer tissues, but not in adjacent normal tissues. High expression is found in the tumor component of some noninvasive superficial lesions and in invasive and metastatic urothelial cancers.

Post-translational modifications. N-glycosylated and O-glycosylated.

Induction. Up-regulated in migrating keratinocytes during epithelization of incisional skin wounds.

RefSeq proteins (1): NP_055215* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR016054	LY6_UPA_recep-like	Domain
IPR045860	Snake_toxin-like_sf	Homologous_superfamily

Pfam: PF00021

UniProt features (31 total): strand 13, glycosylation site 4, compositionally biased region 3, turn 2, helix 2, domain 2, signal peptide 1, chain 1, propeptide 1, region of interest 1, lipid moiety-binding region 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
6IOM	X-RAY DIFFRACTION	2.59
6ION	X-RAY DIFFRACTION	2.75

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O95274-F1	74.61	0.51

Antibody-complex structures (SAbDab): 1 — 6ION

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 326

Glycosylation sites (4): 118, 163, 176, 183

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-163125	Post-translational modification: synthesis of GPI-anchored proteins
R-HSA-392499	Metabolism of proteins
R-HSA-597592	Post-translational protein modification

MSigDB gene sets: 141 (showing top): JAEGER_METASTASIS_DN, ENK_UV_RESPONSE_KERATINOCYTE_UP, AREB6_01, NAGASHIMA_NRG1_SIGNALING_UP, MONNIER_POSTRADIATION_TUMOR_ESCAPE_UP, AMIT_EGF_RESPONSE_480_MCF10A, GOBP_NEGATIVE_REGULATION_OF_MUSCLE_CELL_APOPTOTIC_PROCESS, MODULE_379, RUTELLA_RESPONSE_TO_CSF2RB_AND_IL4_UP, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM1, RUTELLA_RESPONSE_TO_HGF_VS_CSF2RB_AND_IL4_DN, MODULE_88, MODULE_242, GOBP_CELL_SUBSTRATE_ADHESION, CTTTGTA_MIR524

GO Biological Process (2): cell-matrix adhesion (GO:0007160), negative regulation of smooth muscle cell apoptotic process (GO:0034392)

GO Molecular Function (1): laminin binding (GO:0043236)

GO Cellular Component (5): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615), plasma membrane (GO:0005886), side of membrane (GO:0098552), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Post-translational protein modification	1
Metabolism of proteins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
membrane	2
cell-substrate adhesion	1
negative regulation of muscle cell apoptotic process	1
smooth muscle cell apoptotic process	1
regulation of smooth muscle cell apoptotic process	1
protein binding	1
extracellular matrix binding	1
cell periphery	1
leaflet of membrane bilayer	1

Protein interactions and networks

STRING

946 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LYPD3	AGR2	O95994	972
LYPD3	AGR3	Q8TD06	893
LYPD3	DAG1	Q14118	756
LYPD3	PLAUR	Q03405	685
LYPD3	PLAU	P00749	550
LYPD3	PINLYP	A6NC86	542
LYPD3	LY6L	H3BQJ8	540
LYPD3	CD59	P13987	536
LYPD3	PHLDB3	Q6NSJ2	536
LYPD3	TEX101	Q9BY14	521
LYPD3	MMP14	P50281	516
LYPD3	PATE3	B3GLJ2	507
LYPD3	ESR1	P03372	501
LYPD3	ZNF575	Q86XF7	468
LYPD3	PATE2	Q6UY27	447

IntAct

23 interactions, top by confidence:

A	B	Type	Score
LYPD3	SCAMP1	psi-mi:“MI:0914”(association)	0.640
Trim69		psi-mi:“MI:0915”(physical association)	0.400
LYPD3	AURKA	psi-mi:“MI:0915”(physical association)	0.370
BAG4	LYPD3	psi-mi:“MI:0915”(physical association)	0.370
BRMS1	LYPD3	psi-mi:“MI:0915”(physical association)	0.370
LYPD3	CASP8	psi-mi:“MI:0915”(physical association)	0.370
CHEK2	LYPD3	psi-mi:“MI:0915”(physical association)	0.370
ERBB2	LYPD3	psi-mi:“MI:0915”(physical association)	0.370
IGF1R	LYPD3	psi-mi:“MI:0915”(physical association)	0.370
LSP1	LYPD3	psi-mi:“MI:0915”(physical association)	0.370
PALB2	LYPD3	psi-mi:“MI:0915”(physical association)	0.370
LYPD3	PPM1D	psi-mi:“MI:0915”(physical association)	0.370
PTPRJ	LYPD3	psi-mi:“MI:0915”(physical association)	0.370
RB1CC1	LYPD3	psi-mi:“MI:0915”(physical association)	0.370
SMAD4	LYPD3	psi-mi:“MI:0915”(physical association)	0.370
LYPD3	STK11	psi-mi:“MI:0915”(physical association)	0.370
LYPD3	CLASP2	psi-mi:“MI:0914”(association)	0.350
TEX14	DNAJB6	psi-mi:“MI:0914”(association)	0.350
LYPD3	TNPO2	psi-mi:“MI:0914”(association)	0.350
LYPD3	NEMP1	psi-mi:“MI:0914”(association)	0.350
INSR	BLTP3B	psi-mi:“MI:0914”(association)	0.350
PCGF5	LYPD3	psi-mi:“MI:0914”(association)	0.350

BioGRID (281): VDAC3 (Affinity Capture-MS), XPO7 (Affinity Capture-MS), TTI2 (Affinity Capture-MS), ATP2B4 (Affinity Capture-MS), BZW2 (Affinity Capture-MS), BZW1 (Affinity Capture-MS), SLC9A1 (Affinity Capture-MS), FLVCR1 (Affinity Capture-MS), TNPO2 (Affinity Capture-MS), SYMPK (Affinity Capture-MS), RBM26 (Affinity Capture-MS), PHTF2 (Affinity Capture-MS), TMEM214 (Affinity Capture-MS), GPAA1 (Affinity Capture-MS), TARBP1 (Affinity Capture-MS)

ESM2 similar proteins: A2VE33, A8HDK4, A8S6B0, C0STK8, C0STK9, I6PG79, O12962, O55006, O55162, O57690, O95274, P0DQP7, P0DQX3, P0DUK5, P0DUK6, P35459, P35460, P58019, P60591, P60592, P81827, P81828, P82143, P82144, P83121, Q05588, Q3UN54, Q66H42, Q6MG58, Q6UWN5, Q6UX82, Q78CF9, Q7LZI1, Q7LZI2, Q7TQN2, Q8BLC3, Q8N2G4, Q8VEN2, Q90358, Q91YK8

Diamond homologs: O55162, O95274, Q91YK8

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 24 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
protein autophosphorylation	5	31.6×	2e-04
negative regulation of cell population proliferation	5	9.2×	5e-03
negative regulation of apoptotic process	5	7.5×	1e-02

Disease & clinical

Clinical variants and AI predictions

ClinVar

61 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	48
Likely benign	2
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

621 predictions. Top by Δscore:

Variant	Effect	Δscore
19:43461844:TTAG:T	acceptor_gain	1.0000
19:43461845:TAG:T	acceptor_gain	1.0000
19:43461846:AG:A	acceptor_gain	1.0000
19:43461848:C:CC	acceptor_gain	1.0000
19:43463121:CTCAC:C	donor_loss	1.0000
19:43463123:CACCT:C	donor_loss	1.0000
19:43463124:A:T	donor_loss	1.0000
19:43463124:ACCTG:A	donor_gain	1.0000
19:43463125:C:CT	donor_loss	1.0000
19:43463125:CCTG:C	donor_gain	1.0000
19:43463125:CCTGC:C	donor_gain	1.0000
19:43463128:G:A	donor_gain	1.0000
19:43463283:ATTAC:A	acceptor_gain	1.0000
19:43463284:TTAC:T	acceptor_gain	1.0000
19:43463285:TAC:T	acceptor_gain	1.0000
19:43463285:TACCT:T	acceptor_loss	1.0000
19:43463286:AC:A	acceptor_gain	1.0000
19:43463287:CC:C	acceptor_gain	1.0000
19:43463288:C:CC	acceptor_gain	1.0000
19:43463291:C:CT	acceptor_gain	1.0000
19:43463292:G:T	acceptor_gain	1.0000
19:43463301:C:CT	acceptor_gain	1.0000
19:43463301:C:T	acceptor_gain	1.0000
19:43463302:G:T	acceptor_gain	1.0000
19:43463595:GGAC:G	donor_loss	1.0000
19:43463596:GAC:G	donor_loss	1.0000
19:43463598:C:A	donor_loss	1.0000
19:43463601:G:A	donor_gain	1.0000
19:43463766:TGGA:T	acceptor_gain	1.0000
19:43463770:C:CC	acceptor_gain	1.0000

AlphaMissense

2203 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:43461726:G:C	N222K	0.998
19:43461726:G:T	N222K	0.998
19:43463152:A:C	F173C	0.998
19:43463155:C:G	C172S	0.997
19:43463156:A:T	C172S	0.997
19:43463639:G:C	N114K	0.997
19:43463639:G:T	N114K	0.997
19:43464354:C:G	C61S	0.997
19:43464355:A:T	C61S	0.997
19:43461730:C:G	C221S	0.996
19:43461731:A:T	C221S	0.996
19:43461814:C:G	C193S	0.996
19:43461815:A:T	C193S	0.996
19:43463154:G:C	C172W	0.996
19:43463156:A:G	C172R	0.996
19:43463251:C:G	C140S	0.996
19:43463252:A:T	C140S	0.996
19:43463675:G:C	F102L	0.996
19:43463675:G:T	F102L	0.996
19:43463677:A:G	F102L	0.996
19:43461815:A:G	C193R	0.995
19:43461823:A:T	V190D	0.995
19:43463151:G:C	F173L	0.995
19:43463151:G:T	F173L	0.995
19:43463153:A:G	F173L	0.995
19:43463187:G:C	C161W	0.995
19:43463188:C:G	C161S	0.995
19:43463188:C:T	C161Y	0.995
19:43463189:A:T	C161S	0.995
19:43463252:A:G	C140R	0.995

dbSNP variants (sampled 300 via entrez): RS1000008650 (19:43462424 G>C), RS1000062519 (19:43462778 C>T), RS1000579335 (19:43467039 C>T), RS1001009941 (19:43461184 A>C,G), RS1001138918 (19:43465130 T>C), RS1001976838 (19:43465525 G>A), RS1003125420 (19:43462617 A>G), RS1003346279 (19:43465205 G>A), RS1003377302 (19:43465423 G>A,C), RS1003727613 (19:43460958 G>A), RS1004092301 (19:43464669 C>G), RS1004569940 (19:43465064 G>A,T), RS1005274412 (19:43463975 C>A,G,T), RS1005614800 (19:43464331 C>T), RS1005628974 (19:43460599 G>A)

Disease associations

OMIM: gene MIM:609484 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST002652_14	Cotinine glucuronidation	4.000000e-08

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0006508	cotinine glucuronidation measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression	5
sodium arsenite	decreases expression, increases expression	2
entinostat	increases expression, affects cotreatment	2
Panobinostat	affects cotreatment, increases expression	2
Air Pollutants	decreases expression, increases abundance, increases expression	2
Smoke	decreases expression, increases abundance, increases expression	2
Tobacco Smoke Pollution	affects expression, increases expression	2
propionaldehyde	increases expression	1
sodium arsenate	decreases expression, increases abundance	1
pyrogallol 1,3-dimethyl ether	affects cotreatment, increases expression	1
2-methyl-4-isothiazolin-3-one	increases expression	1
ethyl-p-hydroxybenzoate	increases expression	1
beta-lapachone	increases expression	1
afimoxifene	decreases reaction, decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
bleomycetin	increases expression	1
cupric chloride	decreases expression	1
benazol P	affects expression	1
octa-2,4,6-trienoic acid	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
erucylphospho-N,N,N-trimethylpropylammonium	increases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
LG 100815	decreases expression	1
Leflunomide	decreases expression	1
Arsenic	decreases expression, increases abundance	1
Atrazine	increases expression	1
Benzo(a)pyrene	decreases methylation, affects methylation	1
Calcitriol	increases expression	1
Estradiol	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.